Please login to the form below

Not currently logged in
Email:
Password:

Axentis Pharma takes over cystic fibrosis patents

Swiss biotech company Axentis Pharma has taken over Austrian-based BioDevelops Pharma, acquiring the rights to key cystic fibrosis screening patents.
Swiss biotech company Axentis Pharma has taken over Austrian-based BioDevelops Pharma, acquiring the rights to key cystic fibrosis screening patents.

Three years ago, the Austrian company identified a new approach to treating cystic fibrosis; targeting the process through which the body destroys its own proteins - the direct cause of cystic fibrosis. The patents also cover the second medical use of Velcade in cystic fibrosis.

Joerg Zielasek, president of Axentis Pharma said: "By acquiring the rights to BioDevelops' technology platform, Axentis Pharma is both enhancing its development pipeline and offering patients and investors extensive prospects for the treatment of this disease."

Cystic fibrosis is a hereditary disease caused by a mutation in the CFTR gene found on chromosome 7. The mutation causes increased secretion deposits on mucous membranes. These deposits lead to lung complications that in turn result in high mortality rates among sufferers.

26th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics